87 related articles for article (PubMed ID: 7448829)
1. Enhancement of the antitumor-activity of Corynebacterium parvum by appropriate adjustment of dosage schedules.
Megirian R; Astry CL; Spoor RP; Loose L
Cancer Treat Rep; 1980; 64(8-9):915-20. PubMed ID: 7448829
[TBL] [Abstract][Full Text] [Related]
2. Effects of Corynebacterium parvum alone and in combination with adriamycin in experimental tumor systems.
Houchens DP; Johnson RK; Ovejera A; Gaston MR; Goldin A
Cancer Treat Rep; 1976 Jul; 60(7):823-8. PubMed ID: 1009517
[TBL] [Abstract][Full Text] [Related]
3. Nonspecific stimulation of host defense by Corynebacterium kutscheri. I. Antitumor effect.
Kita E; Nishikawa F; Yagyu Y; Hamuro A; Oku D; Emoto M; Katsui N; Tanikawa I; Kashiba S
Nat Immun Cell Growth Regul; 1989; 8(6):313-24. PubMed ID: 2622460
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy of a murine ovarian carcinoma with Corynebacterium parvum and specific heteroantiserum. I. Activation of peritoneal cells to mediate antibody-dependent cytotoxicity.
Bast RC; Knapp RC; Mitchell AK; Thurston JG; Tucker RW; Schlossman SF
J Immunol; 1979 Nov; 123(5):1945-51. PubMed ID: 489967
[TBL] [Abstract][Full Text] [Related]
5. Corynebacterium parvum treatment of P388 tumor-bearing mice. I. Lysosomal enzyme levels in adherent peritoneal cells and peritoneal lavage fluid.
Astry CL; Loose LD; Megirian R
J Immunopharmacol; 1981; 3(1):29-47. PubMed ID: 7252179
[TBL] [Abstract][Full Text] [Related]
6. Comparative effects of different strains of Corynebacterium parvum on natural cell-mediated cytotoxicity.
Nasrallah AG; Gallagher MT; Priest EL; Trentin JJ
Cancer Res; 1980 Nov; 40(11):4159-64. PubMed ID: 7471057
[TBL] [Abstract][Full Text] [Related]
7. Immunological enhancement of leukemia L1210 by Corynebacterium parvum in allogeneic mice.
Berd DA; Mitchell MS
Cancer Res; 1976 Nov; 36(11 Pt 1):4119-24. PubMed ID: 975053
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the in-vitro antitumor activity of peritoneal cells from mice injected with Corynebacterium parvum and Corynebacterium liquefaciens.
Toge T; Hattori T
Hiroshima J Med Sci; 1979 Jun; 28(2):95-101. PubMed ID: 478988
[No Abstract] [Full Text] [Related]
9. [Antitumor effect of Corynebacterium parvum on C3H mouse bearing MH-134 tumor].
Nakamura K; Miwa H; Hashimoto O; Inoue T; Orita K
Gan To Kagaku Ryoho; 1982 Jul; 9(6):1046-51. PubMed ID: 7184438
[TBL] [Abstract][Full Text] [Related]
10. Effect of thymidine on the toxicity and antitumor activity of ftorafur.
Grossie VB; Loo TL
Cancer Treat Rep; 1981; 65(11-12):1087-91. PubMed ID: 6794908
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of Corynebacterium parvum and retinyl palmitate used in combination on the Lewis lung carcinoma.
Pavelic ZP; Dave S; Bialkowski S; Priore RL; Greco WR
Cancer Res; 1980 Dec; 40(12):4617-21. PubMed ID: 7438095
[TBL] [Abstract][Full Text] [Related]
12. Dose, route, and time dependence of serum lysozyme and antitumor activity following administration of glucan, Corynebacterium parvum, pyran, or lipopolysaccharide to mice.
Gorecka-Tisera A; Proctor JW; Yamamura Y; Harnaha J; Meinert K
J Natl Cancer Inst; 1981 Oct; 67(4):911-5. PubMed ID: 6944557
[TBL] [Abstract][Full Text] [Related]
13. Reduced toxicity and enhanced antitumor effects in mice of the ionophoric drug valinomycin when incorporated in liposomes.
Daoud SS; Juliano RL
Cancer Res; 1986 Nov; 46(11):5518-23. PubMed ID: 3756900
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo.
O'Dwyer PJ; Moyer JD; Suffness M; Harrison SD; Cysyk R; Hamilton TC; Plowman J
Cancer Res; 1994 Feb; 54(3):724-9. PubMed ID: 8306334
[TBL] [Abstract][Full Text] [Related]
15. NTP Toxicology and Carcinogenesis Studies of Dimethyl Methylphosphonate (CAS No. 756-79-6) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1987 Nov; 323():1-172. PubMed ID: 12748730
[TBL] [Abstract][Full Text] [Related]
16. Optimal conditions for antitumor activity of C. parvum against the ascites form of sarcoma 180.
Megirian R; Astry CL; Spoor RP; Loose LD
J Immunopharmacol; 1980; 2(1):99-112. PubMed ID: 7452006
[TBL] [Abstract][Full Text] [Related]
17. NTP Toxicology and Carcinogenesis Studies of Pentachloroanisole (CAS No. 1825-21-4) in F344 Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Apr; 414():1-284. PubMed ID: 12616284
[TBL] [Abstract][Full Text] [Related]
18. [Antitumor effects of Behenoyl-ara-C (BH-AC) in combination with Idarubicin (IDA) in P 388 leukemic cell bearing mice].
Watanabe A; Kuriyama H; Kiyota T
Gan To Kagaku Ryoho; 1996 Feb; 23(3):291-6. PubMed ID: 8712821
[TBL] [Abstract][Full Text] [Related]
19. Administration of interleukin-10 at the time of priming protects Corynebacterium parvum-primed mice against LPS- and TNF-alpha-induced lethality.
Smith SR; Terminelli C; Denhardt G; Narula S; Thorbecke GJ
Cell Immunol; 1996 Nov; 173(2):207-14. PubMed ID: 8912878
[TBL] [Abstract][Full Text] [Related]
20. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
